(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
3 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States...
Stats | |
---|---|
आज की मात्रा | 308 100 |
औसत मात्रा | 250 895 |
बाजार मूल्य | 259.75B |
EPS | ¥0 ( 2024-02-13 ) |
अगली कमाई की तारीख | ( ¥59.41 ) 2024-05-08 |
Last Dividend | ¥65.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 19.69 |
ATR14 | ¥4.42 (0.07%) |
मात्रा सहसंबंध
Sawai Group Holdings Co., सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध |
---|
10 सबसे अधिक नकारात्मक सहसंबंध |
---|
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Sawai Group Holdings Co., सहसंबंध - मुद्रा/वस्त्र
Sawai Group Holdings Co., वित्तीय
Annual | 2022 |
राजस्व: | ¥200.34B |
सकल लाभ: | ¥62.63B (31.26 %) |
EPS: | ¥289.26 |
FY | 2022 |
राजस्व: | ¥200.34B |
सकल लाभ: | ¥62.63B (31.26 %) |
EPS: | ¥289.26 |
FY | 2022 |
राजस्व: | ¥193.82B |
सकल लाभ: | ¥66.65B (34.39 %) |
EPS: | ¥-957.37 |
Financial Reports:
No articles found.
Sawai Group Holdings Co., Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥65.00 (N/A) |
¥0 (N/A) |
¥65.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥65.00 | 2021-09-29 |
Last Dividend | ¥65.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | ¥260.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.89 | -- |
Div. Sustainability Score | 9.15 | |
Div.Growth Potential Score | 3.14 | |
Div. Directional Score | 6.15 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
8522.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7846.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
6998.T | Ex Dividend Knight | 2023-09-28 | Annually | 0 | 0.00% | |
6349.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5204.T | Ex Dividend Junior | 2024-03-18 | Annually | 0 | 0.00% | |
4308.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
3480.T | Ex Dividend Knight | 2023-10-30 | Annually | 0 | 0.00% | |
9368.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
2689.T | Ex Dividend Junior | 2024-06-27 | Annually | 0 | 0.00% | |
8142.T | Ex Dividend Knight | 2024-01-30 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0749 | 1.500 | 8.50 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0392 | 1.200 | 8.69 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0735 | 1.500 | -0.294 | -0.441 | [0.1 - 1] |
payoutRatioTTM | 0.372 | -1.000 | 6.28 | -6.28 | [0 - 1] |
currentRatioTTM | 2.18 | 0.800 | 4.09 | 3.27 | [1 - 3] |
quickRatioTTM | 0.782 | 0.800 | -0.108 | -0.0867 | [0.8 - 2.5] |
cashRatioTTM | 0.254 | 1.500 | 9.70 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.229 | -1.500 | 6.19 | -9.28 | [0 - 0.6] |
interestCoverageTTM | 40.11 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 544.46 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -35.66 | 2.00 | -10.00 | -10.00 | [0 - 20] |
debtEquityRatioTTM | 0.425 | -1.500 | 8.30 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.305 | 1.000 | 8.25 | 8.25 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0968 | 1.000 | -0.0640 | -0.0640 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.267 | 1.000 | 9.63 | 9.63 | [0.2 - 2] |
assetTurnoverTTM | 0.524 | 0.800 | 9.84 | 7.87 | [0.5 - 2] |
Total Score | 9.15 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 16.95 | 1.000 | 8.39 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0735 | 2.50 | -0.189 | -0.441 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -35.66 | 2.00 | -10.00 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.19 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 544.46 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.372 | 1.500 | 6.28 | -6.28 | [0 - 1] |
pegRatioTTM | -0.0515 | 1.500 | -3.68 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.117 | 1.000 | 9.59 | 0 | [0.1 - 0.5] |
Total Score | 3.14 |
Sawai Group Holdings Co.,
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, urogenital organs and the anus, antineoplastic, vitamins, anti-cancer, chemotherapeutic agents, respiratory organ agents, hormone agents, etc. The company's products include atorvastatin, limaprost alfadex, lansoprazole, aprepitant, micafungin sodium, silodosin, blonanserin, oseltamivir, capecitabine, atomoxetine hydrochloride, nalfurafine, memantine hydrochloride, eldecalcitol, bazedoxifene, fexofenadine hydrochloride, dutasteride, pregabalin, duloxetine hydrochloride, morphine sulfate tablets, tosymra nasal spray, zembrace symtouch, and ramelteon tablets. It also manufactures and sells medicinal products. The company sells its generic drugs to distributors, retail stores, and other pharmaceutical manufacturers, as well as directly to medical institutions, such as hospitals, general practitioners, and dispensing pharmacies in Japan; and pharmaceutical products to wholesalers in the United States. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं